2-甲基-2-丙烯酸2-(4-吗啉基)乙基酯 | 2997-88-8

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 中文名称: 2-甲基-2-丙烯酸2-(4-吗啉基)乙基酯
• 中文别名: 甲基丙烯酸[2-(4-吗啉基)乙基]酯；2-正吗啉乙基甲基丙烯酸酯
• 英文名称: 2-N-morpholinoethyl methacrylate
• 英文别名: 2-(N-morpholino)ethyl methacrylate；2-N-(morpholino)ethyl methacrylate；morpholinoethyl methacrylate；2-methyl-acrylic acid 2-morpholin-4-yl-ethyl ester；methacrylic acid-(2-morpholino-ethyl ester)；Methacrylsaeure-(2-morpholino-aethylester)；2-Morpholinoethyl methacrylate；2-morpholin-4-ylethyl 2-methylprop-2-enoate
• CAS: 2997-88-8
• 化学式: C₁₀H₁₇NO₃
• mdl: MFCD00080577
• 分子量: 199.25
• InChiKey: MNZNJOQNLFEAKG-UHFFFAOYSA-N

物化性质

• 熔点：
  78℃/1.7mbar
• 沸点：
  81°C/1mmHg(lit.)
• 密度：
  1.045g/ml
• 闪点：
  >110℃

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  38.8
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险类别码：
  R20/21/22
• 安全说明：
  S26,S36
• WGK Germany：
  3
• 危险标志：
  GHS07
• 危险性描述：
  H319
• 危险性防范说明：
  P305 + P351 + P338
• 储存条件：
  室温

反应信息

• 作为产物：
  描述：

  2-吗啉乙醇 、 甲基丙烯酸甲酯 在 对苯二胺 、 苯 作用下， 生成 2-甲基-2-丙烯酸2-(4-吗啉基)乙基酯
  参考文献：
  名称：

  Amino alcohol esters of the alpha substituted acrylic acids

  摘要：

  公开号：

  US02138763A1

文献信息

• [EN] A DENTAL COMPOSITION<br/>[FR] COMPOSITION DENTAIRE
  申请人：STICK TECH OY

  公开号：WO2020035321A1

  公开（公告）日：2020-02-20

  A dental composition comprising10-50 wt-% of a methacrylate-based first matrix component, a polymerisation system and as a second matrix component 1-50 wt-% of a compound having a general formula (I).

  一种牙科组合物，包括10-50重量％的甲基丙烯酸酯基第一基体组分，一个聚合体系，以及作为第二基体组分的具有一般式(I)的化合物，其含量为1-50重量％。
• BORATE-BASED BASE GENERATOR, AND BASE-REACTIVE COMPOSITION COMPRISING SUCH BASE GENERATOR
  申请人：WAKO PURE CHEMICAL INDUSTRIES, LTD.

  公开号：US20160340374A1

  公开（公告）日：2016-11-24

  An object of the present invention is to provide a compound which is capable of attaining a composition having high storage stability without reacting with a base-reactive compound, even in the case of storage for a long period of time in a mixed state with the base-reactive compound, such as an epoxy-based compound, as well as capable of generating a strong base (guanidines, biguanides, phosphazenes or phosphoniums) by irradiation of light (active energy rays) or heating; a base generator comprising the compound; and a base-reactive composition comprising the base generator and the base-reactive compound. The present invention relates to the compound represented by the general formula (A); the base generator comprising the compound; and the base-reactive composition comprising the base generator and the base-reactive compound. (wherein R 1 represents an alkyl group; an arylalkynyl group which may be substituted with a halogen atom, an alkyl group, an alkoxy group, or an alkylthio group; an alkenyl group; a 2-furylethynyl group; a 2-thiophenylethynyl group; or a 2,6-dithianyl group; R 2 to R 4 each independently represent an alkyl group; an arylalkynyl group which may be substituted with a halogen atom, an alkyl group, an alkoxy group, or an alkylthio group; the aryl group which may be substituted with a halogen atom, an alkyl group, an alkoxy group, or an alkylthio group; a furanyl group; a thienyl group; or an N-alkyl-substituted pyrrolyl group; Z + represents an ammonium cation having a guanidinium group, a biguanidium group or a phosphazenium group, or a phosphonium cation.)

  本发明的目的是提供一种化合物，能够在与碱反应性化合物混合状态长时间存储的情况下，仍能获得具有高储存稳定性的组合物，而不与碱反应性化合物发生反应，同时还能通过光照（活性能量射线）或加热产生强碱（胍胺、双胍胺、磷氮烷或磷銨）；包括该化合物的碱发生器；以及包括该碱发生器和碱反应性化合物的碱反应性组合物。本发明涉及由通式（A）表示的化合物；包括该化合物的碱发生器；以及包括该碱发生器和碱反应性化合物的碱反应性组合物。（其中R1代表烷基；可能被卤素原子、烷基、烷氧基或烷硫基取代的芳基炔基；烯基；2-呋喃基炔基；2-噻吩基炔基；或2,6-二硫基基；R2到R4各自独立地代表烷基；可能被卤素原子、烷基、烷氧基或烷硫基取代的芳基炔基；可能被卤素原子、烷基、烷氧基或烷硫基取代的芳基；呋喃基；噻吩基；或N-烷基取代的吡咯基；Z+代表具有胍胺基团、双胍胺基团或磷氮烷基团的铵阳离子，或磷銨阳离子。）
• [EN] THERAPEUTIC COMPOUNDS<br/>[FR] COMPOSÉS THÉRAPEUTIQUES
  申请人：ALLERGAN INC

  公开号：WO2009137412A1

  公开（公告）日：2009-11-12

  Compounds comprising formula (I) or a pharmaceutically acceptable salt thereof, a dashed line represent the presence or absence of a double bond, are disclosed, wherein J1, J2, U1, B, Y, and A are as described in claims 1-12. Methods, compositions, and medicaments related thereto are also disclosed, for treating glaucoma, inflammatory bowel disease and baldness.

  公开了包含式（I）或其药用可接受的盐的化合物，其中虚线表示双键的存在或缺失，其中J1、J2、U1、B、Y和A如权利要求1-12中所述。还公开了与之相关的治疗青光眼、炎症性肠病和脱发的方法、组合物和药物。
• [EN] THERAPEUTIC CYCLOPENTANE DERIVATIVES<br/>[FR] DÉRIVÉS THÉRAPEUTIQUES DE CYCLOPENTANE
  申请人：ALLERGAN INC

  公开号：WO2009137413A1

  公开（公告）日：2009-11-12

  Compounds comprising formula (I) or a pharmaceutically acceptable salt thereof, are disclosed, wherein B, Y, and A are as described in claims 1-10. Methods, compositions, and medicaments related thereto are also disclosed, for treating baldness, glaucoma or inflammatory bowel diseases.

  公开了包含式(I)或其药用可接受的盐的化合物，其中B、Y和A如权利要求1-10中所述。还公开了与之相关的治疗脱发、青光眼或炎症性肠病的方法、组合物和药物。
• COSMETIC COMPOSITION COMPRISING AT LEAST ONE CATIONIC COPOLYMER AND AT LEAST ONE ANIONIC ASSOCIATIVE POLYMER AND COSMETIC TREATMENT PROCESSES USING SAID COMPOSITION
  申请人：BIGANSKA Olga

  公开号：US20090074692A1

  公开（公告）日：2009-03-19

  The disclosure relates to novel cosmetic compositions comprising, in a cosmetically acceptable medium: (i) at least one cationic polymer which are produced by polymerization of a mixture of monomers comprising: a) at least one vinyl monomer substituted with at least one amino group, b) at least one hydrophobic nonionic vinyl monomer, c) at least one associative vinyl monomer, and e) at least one hydroxylated nonionic vinyl monomer, and (ii) at least one anionic associative polymers.

  该披露涉及新型化妆品组合物，包括在适合用于化妆的介质中的：(i) 至少一种阳离子聚合物，其由包括：a) 至少一种含有至少一个氨基团的乙烯单体，b) 至少一种疏水非离子乙烯单体，c) 至少一种关联性乙烯单体，和e) 至少一种羟基化非离子乙烯单体的单体混合物聚合而成，以及(ii) 至少一种阴离子关联性聚合物。